The Use of RNA-based Treatments in the Field of Cancer Immunotherapy

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2023 Jul 7

PMID 37420174

Authors

Mohammad Chehelgerdi

Matin Chehelgerdi

Affiliations

Soon will be listed here.

Abstract

Over the past several decades, mRNA vaccines have evolved from a theoretical concept to a clinical reality. These vaccines offer several advantages over traditional vaccine techniques, including their high potency, rapid development, low-cost manufacturing, and safe administration. However, until recently, concerns over the instability and inefficient distribution of mRNA in vivo have limited their utility. Fortunately, recent technological advancements have mostly resolved these concerns, resulting in the development of numerous mRNA vaccination platforms for infectious diseases and various types of cancer. These platforms have shown promising outcomes in both animal models and humans. This study highlights the potential of mRNA vaccines as a promising alternative approach to conventional vaccine techniques and cancer treatment. This review article aims to provide a thorough and detailed examination of mRNA vaccines, including their mechanisms of action and potential applications in cancer immunotherapy. Additionally, the article will analyze the current state of mRNA vaccine technology and highlight future directions for the development and implementation of this promising vaccine platform as a mainstream therapeutic option. The review will also discuss potential challenges and limitations of mRNA vaccines, such as their stability and in vivo distribution, and suggest ways to overcome these issues. By providing a comprehensive overview and critical analysis of mRNA vaccines, this review aims to contribute to the advancement of this innovative approach to cancer treatment.

Citing Articles

Advances and prospects of RNA delivery nanoplatforms for cancer therapy.

Attia M, Kijanka G, Nguyen N, Zhang J, An H Acta Pharm Sin B. 2025; 15(1):52-96.

PMID: 40041887 PMC: 11873661. DOI: 10.1016/j.apsb.2024.09.009.

Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy.

Delgado-Almenta V, Blaya-Canovas J, Calahorra J, Lopez-Tejada A, Grinan-Lison C, Granados-Principal S Pharmaceutics. 2025; 17(2).

PMID: 40006583 PMC: 11859086. DOI: 10.3390/pharmaceutics17020216.

Apolipoprotein Fusion Enables Spontaneous Functionalization of mRNA Lipid Nanoparticles with Antibody for Targeted Cancer Therapy.

Park W, Choi J, Hwang J, Kim S, Kim Y, Shim M ACS Nano. 2025; 19(6):6412-6425.

PMID: 39908463 PMC: 11841042. DOI: 10.1021/acsnano.4c16562.

Emerging Frontiers in Colorectal Cancer Therapy: From Targeted Molecules to Immunomodulatory Breakthroughs and Cell-Based Approaches.

Fatemi N, Mirbahari S, Tierling S, Sanjabi F, Shahrivari S, AmeliMojarad M Dig Dis Sci. 2025; .

PMID: 39869166 DOI: 10.1007/s10620-024-08774-2.

mRNA vaccines in the context of cancer treatment: from concept to application.

Fu Q, Zhao X, Hu J, Jiao Y, Yan Y, Pan X J Transl Med. 2025; 23(1):12.

PMID: 39762875 PMC: 11702060. DOI: 10.1186/s12967-024-06033-6.

References

Gebre M, Rauch S, Roth N, Yu J, Chandrashekar A, Mercado N . Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. Nature. 2021; 601(7893):410-414. PMC: 8770133. DOI: 10.1038/s41586-021-04231-6. View

Tome I, Francisco V, Fernandes H, Ferreira L . High-throughput screening of nanoparticles in drug delivery. APL Bioeng. 2021; 5(3):031511. PMC: 8397474. DOI: 10.1063/5.0057204. View

Van der Jeught K, De Koker S, Bialkowski L, Heirman C, Joe P, Perche F . Dendritic Cell Targeting mRNA Lipopolyplexes Combine Strong Antitumor T-Cell Immunity with Improved Inflammatory Safety. ACS Nano. 2018; 12(10):9815-9829. DOI: 10.1021/acsnano.8b00966. View

Liang Y, Zhang J, Yuan R, Wang M, He P, Su J . Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2. Cell Discov. 2022; 8(1):17. PMC: 8847466. DOI: 10.1038/s41421-022-00383-5. View

Janssens I, Campillo Davo D, Van den Bos J, De Reu H, Berneman Z, Wens I . Engineering of regulatory T cells by means of mRNA electroporation in a GMP-compliant manner. Cytotherapy. 2022; 24(6):659-672. DOI: 10.1016/j.jcyt.2022.01.001. View

Evers M, Du W, Yang Q, Kooijmans S, Vink A, van Steenbergen M . Delivery of modified mRNA to damaged myocardium by systemic administration of lipid nanoparticles. J Control Release. 2022; 343:207-216. DOI: 10.1016/j.jconrel.2022.01.027. View

Boudewijns S, Bloemendal M, De Haas N, Westdorp H, Bol K, Schreibelt G . Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. Cancer Immunol Immunother. 2020; 69(3):477-488. PMC: 7044256. DOI: 10.1007/s00262-019-02466-x. View

Bahiri Elitzur S, Cohen-Kupiec R, Yacobi D, Fine L, Apt B, Diament A . Prokaryotic rRNA-mRNA interactions are involved in all translation steps and shape bacterial transcripts. RNA Biol. 2021; 18(sup2):684-698. PMC: 8782165. DOI: 10.1080/15476286.2021.1978767. View

Mund S, MacPhee D, Campbell J, Honaramooz A, Wobeser B, Barber S . Macroscopic, Histologic, and Immunomodulatory Response of Limb Wounds Following Intravenous Allogeneic Cord Blood-Derived Multipotent Mesenchymal Stromal Cell Therapy in Horses. Cells. 2021; 10(11). PMC: 8616408. DOI: 10.3390/cells10112972. View

10.

Billingsley M, Singh N, Ravikumar P, Zhang R, June C, Mitchell M . Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering. Nano Lett. 2020; 20(3):1578-1589. PMC: 7313236. DOI: 10.1021/acs.nanolett.9b04246. View

11.

Lokugamage M, Vanover D, Beyersdorf J, Hatit M, Rotolo L, Echeverri E . Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nat Biomed Eng. 2021; 5(9):1059-1068. PMC: 10197923. DOI: 10.1038/s41551-021-00786-x. View

12.

Karollus A, Avsec Z, Gagneur J . Predicting mean ribosome load for 5'UTR of any length using deep learning. PLoS Comput Biol. 2021; 17(5):e1008982. PMC: 8136849. DOI: 10.1371/journal.pcbi.1008982. View

13.

Elong Ngono A, Syed T, Nguyen A, Regla-Nava J, Susantono M, Spasova D . CD8 T cells mediate protection against Zika virus induced by an NS3-based vaccine. Sci Adv. 2020; 6(45). PMC: 7673678. DOI: 10.1126/sciadv.abb2154. View

14.

Guminska N, Zakrys B, Milanowski R . A New Type of Circular RNA derived from Nonconventional Introns in Nuclear Genes of Euglenids. J Mol Biol. 2020; 433(3):166758. DOI: 10.1016/j.jmb.2020.166758. View

15.

Appelberg S, John L, Pardi N, Vegvari A, Bereczky S, Ahlen G . Nucleoside-Modified mRNA Vaccines Protect IFNAR Mice against Crimean-Congo Hemorrhagic Fever Virus Infection. J Virol. 2021; 96(3):e0156821. PMC: 8826901. DOI: 10.1128/JVI.01568-21. View

16.

Mulder F, Klufah F, Janssen F, Farshadpour F, Willems S, de Bree R . Presence of Human Papillomavirus and Epstein-Barr Virus, but Absence of Merkel Cell Polyomavirus, in Head and Neck Cancer of Non-Smokers and Non-Drinkers. Front Oncol. 2021; 10:560434. PMC: 7855709. DOI: 10.3389/fonc.2020.560434. View

17.

Sahin U, Oehm P, Derhovanessian E, Jabulowsky R, Vormehr M, Gold M . An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020; 585(7823):107-112. DOI: 10.1038/s41586-020-2537-9. View

18.

Maksimowski N, Song X, Bae E, Reich H, John R, Pei Y . Follistatin-Like-1 (FSTL1) Is a Fibroblast-Derived Growth Factor That Contributes to Progression of Chronic Kidney Disease. Int J Mol Sci. 2021; 22(17). PMC: 8431028. DOI: 10.3390/ijms22179513. View

19.

Dorrie J, Schaft N, Schuler G, Schuler-Thurner B . Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells-An Update. Pharmaceutics. 2020; 12(2). PMC: 7076681. DOI: 10.3390/pharmaceutics12020092. View

20.

Martinez-Cortes F, Servin-Blanco R, Dominguez-Romero A, Munguia M, Guzman Valle J, Odales J . Generation of cancer vaccine immunogens derived from Oncofetal antigen (OFA/iLRP) using variable epitope libraries tested in an aggressive breast cancer model. Mol Immunol. 2021; 139:65-75. DOI: 10.1016/j.molimm.2021.08.013. View